VIDA Diagnostics, Inc. (“VIDA”), the leader in precision pulmonary informatics, announced the completion of a $5.1 million Series B round of equity financing. Funding was led by Chartline Capital Partners. Rittenhouse Ventures, Next Level Ventures, Rural Vitality Fund II, Iowa Seed Fund II, and Northern California Investment Fund also participated in the round.
The investment will be used to expand Coralville-based VIDA’s commercialization efforts, hire additional talent, and enhance its clinical software and services. VIDA will advance its industry-leading solutions for pulmonary disease management, including lung cancer, COPD, and asthma.
Click here for full release on PRNewswire.